 BOSTON, Nov. 09, 2022 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patients body, announced today that it will present at two investor conferences this November, the Stifel Healthcare Conference 2022, to be held November 15-16 in New York, and the Jefferies London Healthcare Conference, to be held in London, UK, November 15-17. 